Douglas Lane & Associates, LLC Gilead Sciences, Inc. Transaction History

Douglas Lane & Associates, LLC

$7.1 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 17, 2024	SELL	$73.27 - $83.09 $1,465 - $1,661	-20 Reduced 0.73%	2,731 $221,000
Q3 2023 Oct 16, 2023	SELL	$73.94 - $80.67 $49,170 - $53,645	-665 Reduced 19.47%	2,751 $206,000
Q2 2023 Jul 19, 2023	SELL	$76.01 - $86.7 $23,183 - $26,443	-305 Reduced 8.2%	3,416 $263,000
Q1 2023 Apr 17, 2023	BUY	$77.31 - $88.08 $31,929 - $36,377	413 Added 12.48%	3,721 $308,000
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $18,571 - $26,662	-298 Reduced 8.26%	3,308 $283,000
Q4 2022 Jan 17, 2023	BUY	$62.32 - $89.47 $224,725 - $322,628	3,606 New	3,606 $310,000
Q1 2022 Apr 25, 2022	SELL	$57.92 - $72.58 $234,923 - $294,384	-4,056 Closed	0 $0
Q4 2021 Jan 25, 2022	SELL	$64.88 - $73.64 $1,946 - $2,209	-30 Reduced 0.73%	4,056 $295,000
Q3 2021 Oct 21, 2021	BUY	$67.69 - $73.03 $9,544 - $10,297	141 Added 3.57%	4,086 $285,000
Q2 2021 Jul 19, 2021	BUY	$63.47 - $69.35 $8,504 - $9,292	134 Added 3.52%	3,945 $272,000
Q1 2021 Apr 19, 2021	SELL	$60.0 - $68.46 $42,780 - $48,811	-713 Reduced 15.76%	3,811 $246,000
Q4 2020 Jan 14, 2021	BUY	$56.65 - $64.55 $11,726 - $13,361	207 Added 4.79%	4,524 $264,000
Q3 2020 Oct 19, 2020	SELL	$62.1 - $78.08 $21,735 - $27,328	-350 Reduced 7.5%	4,317 $273,000
Q2 2020 Jul 28, 2020	BUY	$72.34 - $84.0 $33,493 - $38,892	463 Added 11.01%	4,667 $359,000
Q1 2020 Apr 20, 2020	BUY	$62.63 - $80.22 $688 - $882	11 Added 0.26%	4,204 $314,000
Q4 2019 Jan 27, 2020	SELL	$61.62 - $67.78 $25,387 - $27,925	-412 Reduced 8.95%	4,193 $272,000
Q3 2019 Oct 16, 2019	SELL	$62.51 - $69.0 $40,944 - $45,195	-655 Reduced 12.45%	4,605 $292,000
Q2 2019 Jul 08, 2019	SELL	$61.87 - $69.38 $353,153 - $396,021	-5,708 Reduced 52.04%	5,260 $355,000
Q1 2019 Apr 23, 2019	BUY	$62.53 - $70.05 $3,001 - $3,362	48 Added 0.44%	10,968 $713,000
Q4 2018 Jan 17, 2019	SELL	$60.54 - $79.0 $109,456 - $142,832	-1,808 Reduced 14.2%	10,920 $683,000
Q3 2018 Oct 09, 2018	BUY	$71.28 - $78.92 $46,403 - $51,376	651 Added 5.39%	12,728 $983,000
Q2 2018 Jul 23, 2018	SELL	$64.88 - $75.68 $16,219 - $18,920	-250 Reduced 2.03%	12,077 $856,000
Q1 2018 Apr 23, 2018	BUY	$72.84 - $88.8 $10,926 - $13,320	150 Added 1.23%	12,327 $929,000
Q4 2017 Jan 24, 2018	BUY	$71.15 - $83.52 $32,159 - $37,751	452 Added 3.86%	12,177 $872,000
Q3 2017 Oct 19, 2017	BUY	$72.11 - $85.47 $845,489 - $1 Million	11,725	11,725 $950,000

Others Institutions Holding GILD

# of Institutions

1,893

Shares Held

1.02B

Call Options Held

12M

Put Options Held

9.04M

Black Rock Inc. New York, NY

121M
Shares

$10.6 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.2 Billion
0.15% of portfolio
Capital World Investors Los Angeles, CA

76.2M
Shares

$6.72 Billion
0.88% of portfolio
Capital Research Global Investors Los Angeles, CA

60.4M
Shares

$5.32 Billion
0.94% of portfolio
State Street Corp Boston, MA

59.3M
Shares

$5.23 Billion
0.18% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Douglas Lane & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Douglas Lane & Associates, LLC with notifications on news.

Account